Consolidated Balance Sheet

Consolidated balance sheet as at 30 September 2024

€ thousand Note 30.09.2024 30.09.2023
Non-current assets
Intangible assets and goodwill (12) 14,185 15,215
Property, plant and equipment (13) 27,855 28,720
Equity-accounted investments (14) 971 1,456
Other non-current assets (18) 67 70
43,078 45,462
Current assets
Inventories (15) 9,420 9,756
Trade receivables (16) 7,798 9,442
Other current assets (18) 818 691
Current tax assets (10) 214 56
Other financial assets (17) 238 178
Cash and cash equivalents (19) 27,171 5,352
45,658 25,476
ASSETS 88,737 70,937
Equity (20)
Subscribed capital 21,847 21,847
Capital reserves 94,951 93,457
Retained earnings -105,494 -94,161
Other reserves 1,313 627
12,617 21,771
Non-controlling interests 1,269 1,243
Total equity 13,886 23,013
Non-current liabilities
Deferred tax (10) 3,881 3,768
Provisions for post-employment benefits for employees (5) 930 928
Financial liabilities (21) 21,175 24,265
Convertible bonds (22) 4,151 0
Financial liability to Royalty Pharma (23) 18,406 0
Other liabilities (24) 179 966
Deferred income (25) 1,124 518
49,845 30,445
Current liabilities
Provisions (26) 1,106 895
Tax liabilities (10) 24 44
Financial liabilities (21) 11,888 4,741
Convertible bonds (22) 326 0
Trade payables (27) 5,611 5,617
Other liabilities (24) 5,431 3,251
Deferred income (25) 620 2,932
25,006 17,479
EQUITY AND LIABILITIES 88,737 70,937